Homoharringtonine

Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.

Also Known As:

Ceflatonin; Cephalotaxine; Homoharringtonine (3(R))-isomer; Omacetaxine; Omacetaxine Mepesuccinate; Synribo; Cephalotaxine, O3-((2R)-2,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-6-methyl-1-oxoheptyl)-

Networked: 355 relevant articles (42 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Harringtonines: 5
    - Homoharringtonine: 355
      - (3(R))-isomer 3H-labeled homoharringtonine
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Harringtonines: 5
        Homoharringtonine: 355
        (3(R))-isomer 3H-labeled homoharringtonine
  - 4 or More Rings Heterocyclic Compounds
    - Harringtonines: 5
      - Homoharringtonine: 355
        (3(R))-isomer 3H-labeled homoharringtonine

Experts

1.	Jin, Jie: 15 articles (01/2022 - 07/2007)
2.	Cortes, Jorge: 13 articles (01/2017 - 04/2002)
3.	Kantarjian, Hagop: 7 articles (01/2019 - 01/2007)
4.	Wetzler, Meir: 7 articles (01/2016 - 01/2011)
5.	Liu, Jie: 6 articles (01/2021 - 03/2008)
6.	Qian, Wenbin: 6 articles (02/2016 - 12/2007)
7.	Zhang, Yu: 5 articles (01/2022 - 08/2003)
8.	Li, Xia: 5 articles (01/2020 - 02/2017)
9.	Yu, Mengxia: 5 articles (01/2020 - 02/2017)
10.	Li, Yufeng: 5 articles (10/2019 - 07/2013)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/01/2012 - "High-dose homoharringtonine does not clearly increase the complete remission rate of elderly patients with acute myeloid leukemia. " 11/01/1992 - "Homoharringtonine is safe and effective for patients with acute myelogenous leukemia." 04/01/2016 - "Clinical studies have demonstrated that omacetaxine mepesuccinate exerts beneficial effects on acute myelogenous leukemia. " 08/01/2001 - "A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study." 03/01/1989 - "Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia."
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/01/2013 - "Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia." 05/01/2012 - "This study investigated the effect of homoharringtonine (HHT) on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia (CML). " 01/01/2011 - "Omacetaxine mepesuccinate was originally identified more than 35 years ago and initial studies in chronic myeloid leukemia (CML) showed promising activity. " 12/01/2023 - "Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia." 01/01/2023 - "Ribosome structures from cells treated with Homoharringtonine, a drug used against chronic myeloid leukemia, revealed how translation dynamics were altered in situ and resolve the small molecules within the active site of the ribosome. "
3.	Leukemia 01/01/1991 - "Homoharringtonine (HHRT) was shown to be effective against acute leukemia. " 07/01/2015 - "A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells." 06/01/2009 - "To study the resistant related molecules of human leukemia drug resistant K562 cells (K562/HHT) induced by homoharringtonine (HHT). " 07/01/2008 - "This study was to explore the influence of RNA interference (RNAi) targeting HIF-1alpha on sensitivity of human chronic myelogeneous leukemia (CML) K562 cells towards homoharringtonine (HHT). " 05/01/2008 - "In preclinical studies, omacetaxine mepesuccinate induced apoptosis in leukemia cell lines. "
4.	Myeloid Leukemia (Leukemia, Myelocytic) 08/01/2004 - "Homoharringtonine: a new treatment option for myeloid leukemia." 08/01/2009 - "After 4 days of treatment of CML mice with omacetaxine, Gr-1(+)myeloid leukemia cells decreased in the peripheral blood of the treated CML mice. " 02/01/2005 - "(3) The transfected mice could tolerate homoharringtonine 5 approximately 6 folds higher than conventional dose and kept peripheral WBC count at a mean of 3 x 10(9)/L, with the peripheral human myeloid leukemia cells percentage decreasing to less than 5%. " 01/01/2015 - "Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?" 01/01/2017 - "The scope of biological activities of the Cephalotaxus alkaloids is mainly centered on the antileukemic activity of homoharringtonine (HHT) (2), which in particular demonstrated marked benefits in the treatment of orphan myeloid leukemia and was approved as soon as 2009 by European Medicine Agency and by US Food and Drug Administration in 2012. "
5.	Neoplasms (Cancer) 01/01/2019 - "Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. " 05/26/2019 - "This study outlines a simplified approach to identify lead compounds from natural products against several cancer cell lines, and provides the basis to better understand structure activity relationship of the natural product cephalotaxine. " 01/01/2013 - "This study assessed pharmacokinetics and safety of SC omacetaxine in patients with advanced cancers. " 01/01/2013 - "Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors." 09/01/1984 - "For phase II studies of homoharringtonine in solid tumors, a daily dose of 3 mg/m2 for 5 days in patients with extensive prior treatment and 4 mg/m2/day for 5 days in patients with good bone marrow reserve will be utilized. "

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Homoharringtonine
3.	Alkaloids
4.	Aclarubicin
5.	Daunorubicin (Cerubidine)
6.	Tyrosine Kinase Inhibitors
7.	Granulocyte Colony-Stimulating Factor (G-CSF)
8.	Doxorubicin (Adriamycin)
9.	Protein Synthesis Inhibitors
10.	Interferons

Related Therapies and Procedures

1.	Therapeutics
2.	Induction Chemotherapy
3.	Salvage Therapy
4.	Consolidation Chemotherapy
5.	Filtering Surgery